Evidence map›Paper›PMID 39270843›Full record

Trial reportJournal of vascular surgery. Venous and lymphatic disorders2025

Long-term outcomes of mechanochemical ablation using the Clarivein device for the treatment of great saphenous vein incompetence.

Sharon Oud, Tamana Alozai, Yee Lai Lam, Çağdaş Ünlü, Michael Mooij, Michiel A Schreve

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Journal of vascular surgery. Venous and lymphatic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sharon OudDepartment of Surgery, Amsterdam University Medical Centre, Amsterdam, The Netherlands; Department of Surgery, Northwest Clinics, Alkmaar, The Netherlands. Electronic address: sharonoud@hotmail.com.
Tamana AlozaiDepartment of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Yee Lai LamDepartment of Dermatology, Zaans Medical Centre, Zaandam, The Netherlands.
Çağdaş ÜnlüDepartment of Surgery, Northwest Clinics, Alkmaar, The Netherlands; Department of Surgery, Red Cross Hospital, Beverwijk, The Netherlands.
Michael MooijDepartment of Phlebology, Skin and Vein Clinic Oosterwal, Alkmaar, The Netherlands.
Michiel A SchreveDepartment of Surgery, Northwest Clinics, Alkmaar, The Netherlands; Department of Surgery, Red Cross Hospital, Beverwijk, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe short-term anatomical success rates of mechanochemical ablation using the Clarivein device (Merit Medical) in the treatment of great saphenous vein (GSV) incompetence are high. However, the anatomical success rates seem to drop over time. The aim of this study was to determine the long-term outcomes of GSV treatment using the Clarivein and to assess whether specific anatomical features better correlate with clinical or quality of life (QoL)-related outcomes.

methodsThis is a single-center, prospective cohort study in follow-up of a multicenter, randomized controlled trial using Clarivein with liquid polidocanol for the treatment of GSV incompetence. The primary outcome was anatomical success (AS), defined as complete occlusion or a recanalized segment, irrespective of reflux, of <10 cm in length. In addition, reflux-free anatomical success (RF-AS) was determined, and defined as complete occlusion or a recanalized segment with <10 cm of reflux. Clinical success was assessed using the Venous Clinical Severity Score (VCSS), and QoL was assessed using the Dutch version of the Aberdeen Varicose Vein Questionnaire (DAVVQ) and the 36-Item Short Form Health Survey (SF-36). Subgroup analyses were performed based on whether AS or RF-AS was achieved or not.

resultsA total of 109 patients (115 limbs) were included. The mean follow-up time was 8.4 ± 0.9 years (range, 5.5-10.3 years). AS was seen in 60.5% of limbs, and RF-AS was seen in 72.8% of limbs. Compared with baseline, the overall mean VCSS improved from 5.3 ± 2.4 to 4.1 ± 2.4, and the overall median DAVVQ score from 13.5 (interquartile range [IQR], 8.7-20.0) to 10.5 (IQR, 5.3-16.2) (P < .001). Improvement in VCSS was only significant in patients with successful treatment: from 5.5 ± 2.7 to 3.7 ± 2.5 (P < .001) if AS was achieved and from 5.0 ± 1.7 to 4.5 ± 1.9 (P = .20) if AS was not achieved. The same results were found for DAVVQ scores: improvement from13.5 (IQR, 8.7-20.6) to 10.3 (IQR, 3.0-14.5) (P < .01) if AS was achieved and from 12.9 (IQR, 8.3-19.3) to 10.8 (IQR, 6.7-18.2) (P = .35) if AS was not achieved. Regarding the overall SF-36 scores, the domains of vitality, mental health, and general health worsened significantly.

conclusionsIn over 8 years of follow-up, the anatomical success rate after the treatment of GSV incompetence using the Clarivein device decreased to 60.5%. However, clinical scores and disease-specific QoL still improved significantly compared with baseline. We found no convincing evidence that the absence of reflux correlates better with clinical and QoL-related outcomes compared with recanalization irrespective of reflux.

Indexed as

Quality of LifeSaphenous VeinVenous InsufficiencyAblation TechniquesAdultAgedFemaleHumansMaleMiddle AgedPolidocanolProspective StudiesSclerosing SolutionsSclerotherapyTime FactorsTreatment OutcomePolidocanolSclerosing SolutionsClariveinGreat saphenous veinMechanochemical ablationVaricose veinsVenous insufficiency

Identifiers

PMID39270843
PMCPMC11764119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.